Jason Scott Slakter
Chief Executive Officer at Jason S. Slakter MD PC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jay L. Federman | M | 86 |
American Ophthalmological Society
 American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year.
The Retina Society
Macula Society
American Society of Retinal Specialists
| - |
| Thomas Ciulla | M | 59 |
Macula Society
The Retina Society
American Society of Retinal Specialists
| - |
| Jordi Monés Carilla | M | 62 |
American Society of Retinal Specialists
Macula Society
The Retina Society
| - |
| Glenn L. Stoller | M | 60 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.
The Retina Society
American Society of Retinal Specialists
| - |
| David Cohen | M | 59 |
New York University School of Medicine
| 31 years |
| Donald Gagliano | M | 71 |
The Retina Society
American Society of Retinal Specialists
| - |
| William L. Hutton | M | - |
The Retina Society
American Society of Retinal Specialists
| - |
| Emily Chew | F | - |
American Ophthalmological Society
American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | - |
| Nickolay Voronin | M | - |
Orphion Therapeutics, Inc.
 Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | - |
| Orrin Devinsky | M | 67 |
New York University School of Medicine
| - |
| Pravin Dugel | M | 60 |
American Society of Retinal Specialists
| - |
| Bruce A. Hanna | M | 80 |
New York University School of Medicine
| 45 years |
| Hanna John Shammas | M | - |
American Ophthalmological Society
American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | - |
| Julia Haller | M | 69 |
Macula Society
| - |
| Jeffrey S. Heier | M | 63 |
Macula Society
| - |
| Caroline Blaum | F | - |
New York University School of Medicine
| - |
| Kourous Rezaei | M | - |
American Society of Retinal Specialists
| - |
| Jun Shyan Wong | M | 58 |
The Retina Society
| 17 years |
| Marc Bell | M | 56 |
New York University School of Medicine
| - |
| Daniel Malamud | M | - |
New York University School of Medicine
| - |
| Scott William Cousins | M | - |
American Society of Retinal Specialists
| - |
| Antony Loebel | M | 64 |
New York University School of Medicine
| - |
| Dimitri Azar | M | 65 |
American Ophthalmological Society
American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | - |
| Peter Francis | M | 55 |
Macula Society
| - |
| Donald J. D'Amico | M | - |
The Retina Society
| - |
| Cheryl Pegus | M | 60 |
New York University School of Medicine
| - |
| Michael Yehuda Mashaal | M | 50 |
Orphion Therapeutics, Inc.
Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | - |
| Gregory S. Hageman | M | - |
Macula Society
| - |
| Thomas Errico | M | 72 |
New York University School of Medicine
| - |
| Darrell S. Rigel | M | 73 |
New York University School of Medicine
| - |
| Stanley Zinberg | M | 89 |
New York University School of Medicine
| - |
| Jamie Dimon | M | 68 |
New York University School of Medicine
| - |
| Anthony Welters | M | 69 |
New York University School of Medicine
| - |
| Karen Medina | F | - |
Vitreous Retina Macula Consultants of New York
| 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Irach Taraporewala | M | 68 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 7 years |
| Samuel Backenroth | M | 39 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 9 years |
| Ira Greenstein | M | 63 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 10 years |
| Orin Hirschman | M | 54 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 10 years |
| June Almenoff | M | 67 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 years |
| Thomas M. Riedhammer | M | 76 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 6 years |
| Michael Ferguson | M | 53 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 years |
| Peter K. Kaiser | M | - |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | - |
| Avner Ingerman | M | 60 |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | 2 years |
| Jeffrey Schneebaum | M | - |
Jason S. Slakter MD PC
 Jason S. Slakter MD PC Medical/Nursing ServicesHealth Services Part of ProScan Imaging LLC, Jason S. Slakter MD PC is an ophthalmology imaging core lab. The company is based in Great Neck, NY. The company was founded in 1998 by Jason Scott Slakter and Jeffrey Schneebaum. Jason Scott Slakter has been the CEO since 1998. Jason S. Slakter MD was acquired by WorldCare Clinical LLC on September 03, 2021. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 44 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jason Scott Slakter
- Personal Network
